Journal article

Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy

Anders Perner, Anthony C Gordon, Daniel De Backer, George Dimopoulos, James A Russell, Jeffrey Lipman, Jens-Ulrik Jensen, John Myburgh, Mervyn Singer, Rinaldo Bellomo, Timothy Walsh

Intensive Care Medicine | SPRINGER | Published : 2016

University of Melbourne Researchers


Funding Acknowledgements

AP is member of the steering committee and national investigator of a vasopressin trial in septic shock sponsored by Ferring Pharmaceuticals; his department is reimbursed for his time. The department also receives research funding from Fresenius Kabi and CSL Behring. ACG has received speaker fees from Orion Pharmaceuticals. He has consulted for Ferring Pharmaceuticals, Tenax Therapeutics and received grant support from Orion Pharmaceuticals, Tenax Therapeutics and HCA International with funds paid to his institution. He is the Chief Investigator for two NIHR funded trials in septic shock, VANISH examining vasopressin, and LeoPARDS examining levosimendan. DDB is member of the steering committee of Surviving Sepsis Campaign. He was PI of the SOAP II study that compared dopamine and norepinephrine for the treatment of shock. He is member or contributed to the advisory board of Nestle and Baxter, received honoraria for lectures from Griffols, Edwards Lifesciences and Nihon Kohden, and grant or material for research from Edwards Lifesciences, Pulsion, LiDCO, Vytech, Cheetah Medical, Nexfin, and Imacor, none of these being relevant to the content of this article. GD is a member of advisory boards on severe infections for ASTELLAS, PFIZER, BAYER and MERCK, and has received honorarium fees for lecture tours from ASTELLAS, PFIZER, MERCK, BAXTER, GILEAD while his department is one of the three main partners of EU/FP7 project named "MAGIC BULLET". JM's institution, the George Institute for Global Health, Sydney, has received logistical support; unrestricted grant and reimbursement for travel expenses from Fresenius Kabi in relation to the conduct of the Crystalloid vs. Hydroxyethyl Starch Trial; unrestricted grant and reimbursement for travel expenses and participation on the Advisory Board from Baxter Health in relation to fluid resuscitation research; and unrestricted grant from CSL Bioplasma in relation to fluid resuscitation research. He has received no direct personal remuneration. JR reports patents owned by the University of British Columbia (UBC) that are related to PCSK9 inhibitor(s) and sepsis and related to the use of vasopressin in septic shock. JR is an inventor on these patents. JR is a founder, Director and shareholder in Cyon Therapeutics Inc. (developing a sepsis therapy). Dr. Russell has share options in Leading Biosciences Inc. JR is a shareholder in Molecular You Corp. JR reports receiving consulting fees from Cubist Pharmaceuticals (now owned by Merck; formerly was Trius Pharmaceuticals; developing antibiotics), Ferring Pharmaceuticals (manufactures vasopressin and is developing selepressin), Grifols (sells albumin), La Jolla Pharmaceuticals (developing angiotensin II; JR chairs the DSMB of a trial of angiotensin II), CytoVale Inc. (developing a sepsis diagnostic), and Asahi Kesai Pharmaceuticals of America (AKPA) (developing recombinant thrombomodulin). JR reports having received grant support from Ferring Pharmaceuticals that was provided to and administered by UBC. MS is a co-investigator of the UK Department of Health-funded LeoPARDs trial examining the role of levosimendan in septic shock, and Clinical PI of a large multicenter sepsis biomarker study conducted by the UK Ministry of Defence (DSTL). He is Co-PI of a sub-study of the EU Innovative Medicines Initiative Combacte-Magnet Program. He sits on advisory boards for Biotest assessing the role of immunoglobulins in septic shock, and Bayer's novel amikacin nebuliser therapy for hospital-acquired pneumonia.r He chairs the Data Monitoring Committee for InflaRx's Phase II trial of a novel C5a inhibitor. He is also developing a novel tissue oxygen sensor supported by the Wellcome Trust and the UK Department of Health that is shortly to undergo clinical trials. TSW has received consultancy fees to his institution (Edinburgh University) over the past 5 years from GE Healthcare and Selex; neither were relevant to the content of this article.